The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
297
The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.
Chu de Grenoble
Grenoble, France
NOT_YET_RECRUITINGCHU de Montpellier
Montpellier, France
RECRUITINGNimes University Hospital
Nîmes, France
RECRUITINGChange in iatrogenic drug risk in intervention groups versus control group
Proportion of patients transitioning from intermediate or high to low risk according to Trivalle score (a score between 0-10. A score 0-1 constitutes a low ADE risk (12%), score 2-5 represents an average risk (32%), and a score 6-10 represents a high risk (53%)
Time frame: 3 months after hospitalization
Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups
Number of modifications accepted/number of modifications proposed
Time frame: Hospital discharge (maximum 30 days)
Number of potentially inappropriate medications per patient in each group
Time frame: Hospital discharge (maximum 30 days)
Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent
Number of modifications accepted/number of modifications proposed
Time frame: 3 months after hospital discharge
Number of potentially inappropriate medications per patient in each group
Time frame: 3 months after hospital discharge
Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2)
Hours
Time frame: Hospital discharge (maximum 30 days)
Time required for ransmitting multidisciplinary correspondence documents in B2 group
Hours
Time frame: Hospital discharge (maximum 30 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU de Toulouse
Toulouse, France
Number of multidisciplinary correspondence documents sent to the community acotors in B2 group
Time frame: Hospital discharge (maximum 30 days)
Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group
email, fax or letter
Time frame: Hospital discharge (maximum 30 days)
Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group
Time frame: Hospital discharge (maximum 30 days)
Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group
Time frame: 2 months post discharge
Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2
Time frame: 2 months post hospital discharge
Rate of patients with at least one rehospitalization in each group
Time frame: 3 months after hospital discharge
Mortality rate in each group
Time frame: 3 months after hospital discharge
Healthcare team satisfaction in interventional groups (B1, B2)
Custom-built 7-part questionnaire
Time frame: 3 months after hospital discharge
patient satisfaction in all groups (A, B1, B2)
questionnaire
Time frame: 3 months after hospital discharge